Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
J Cell Biochem ; 119(10): 8574-8587, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30058078

RESUMEN

Hepatitis C virus (HCV) nonstructural protein 5B (NS5B) is an RNA-dependent RNA polymerase that plays a key role in HCV replication, and, hence, NS5B is an attractive target for hepatitis C drug discovery. Hepatitis C is a chronic liver disease affecting the global population significantly. Many NS5B inhibitors targeting active site were launched in recent years, however, still there exists a pressing need for cost-effective therapies with pan genotypic activity and therapies targeting niche HCV population with comorbities and resistant to earlier therapies. The objective of the current study is to identify potential anti-HCV agents from FDA approved drugs that are already in the market for a different disease-Drug repurposing approach. A combination of computational chemistry and computational biology techniques was used to discover potential therapies for hepatitis C targeting the NS5B Thumb I allosteric site. Computational chemistry analysis emphasized the fact that fluvastatin, a lipid lowering agent, and olopatadine, an antihistamine, exhibited good binding affinity to NS5B. In addition, gene set enrichment analysis brought to light the significant overlap between disease characteristic features and the mechanism of action of fluvastatin and olopatadine. The current study concludes the potentially beneficial use of fluvastatin in niche hepatitis C patient population suffering from nonalcoholic fatty liver diseases.


Asunto(s)
Antivirales/química , Biología Computacional/métodos , Reposicionamiento de Medicamentos/métodos , Fluvastatina/química , Hepacivirus/enzimología , Clorhidrato de Olopatadina/química , Proteínas no Estructurales Virales/química , Sitio Alostérico , Antivirales/uso terapéutico , Fluvastatina/metabolismo , Fluvastatina/uso terapéutico , Hepatitis C/tratamiento farmacológico , Hepatitis C/genética , Humanos , Enlace de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas , Ligandos , Redes y Vías Metabólicas/genética , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Clorhidrato de Olopatadina/metabolismo , Clorhidrato de Olopatadina/uso terapéutico , Unión Proteica , Estructura Secundaria de Proteína , Transcriptoma , Interfaz Usuario-Computador , Proteínas no Estructurales Virales/antagonistas & inhibidores
2.
Sci Rep ; 9(1): 7906, 2019 05 27.
Artículo en Inglés | MEDLINE | ID: mdl-31133718

RESUMEN

Drug-target binding kinetics are suggested to be important parameters for the prediction of in vivo drug-efficacy. For G protein-coupled receptors (GPCRs), the binding kinetics of ligands are typically determined using association binding experiments in competition with radiolabelled probes, followed by analysis with the widely used competitive binding kinetics theory developed by Motulsky and Mahan. Despite this, the influence of the radioligand binding kinetics on the kinetic parameters derived for the ligands tested is often overlooked. To address this, binding rate constants for a series of histamine H1 receptor (H1R) antagonists were determined using radioligands with either slow (low koff) or fast (high koff) dissociation characteristics. A correlation was observed between the probe-specific datasets for the kinetic binding affinities, association rate constants and dissociation rate constants. However, the magnitude and accuracy of the binding rate constant-values was highly dependent on the used radioligand probe. Further analysis using recently developed fluorescent binding methods corroborates the finding that the Motulsky-Mahan methodology is limited by the employed assay conditions. The presented data suggest that kinetic parameters of GPCR ligands depend largely on the characteristics of the probe used and results should therefore be viewed within the experimental context and limitations of the applied methodology.


Asunto(s)
Unión Competitiva , Antagonistas de los Receptores Histamínicos H1/farmacocinética , Sondas Moleculares/química , Ensayo de Unión Radioligante/métodos , Receptores Histamínicos H1/metabolismo , Cetirizina/química , Cetirizina/farmacocinética , Conjuntos de Datos como Asunto , Transferencia Resonante de Energía de Fluorescencia/métodos , Colorantes Fluorescentes/química , Colorantes Fluorescentes/farmacocinética , Células HEK293 , Antagonistas de los Receptores Histamínicos H1/química , Humanos , Ligandos , Sondas Moleculares/farmacocinética , Clorhidrato de Olopatadina/química , Clorhidrato de Olopatadina/farmacocinética , Unión Proteica , Pirilamina/química , Pirilamina/farmacocinética , Tritio
3.
J Pharm Sci ; 105(8): 2419-26, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27373838

RESUMEN

Crystal and molecular structures of 2 conformational polymorphs (forms I and II) of olopatadine hydrochloride, an antiallergic agent, are presented. Both crystal modifications crystallize in the monoclinic crystal system with 1 olopatadine hydrochloride molecule in the Z configuration in the asymmetric unit. Molecules are arranged into the centrosymmetric association through the interactions of the intermolecular strong and weak hydrogen bonds of N-H…Cl, O-H…Cl and C-H…Cl, C-H…O types. Conformational change between polymorphs is proved by calculations of a maximum torsion angle deviation (max[Δθ]) and a root-mean-square deviation between the atomic positions (rmsd[r]). The physicochemical characterization of polymorphs is performed by X-ray powder diffraction, infrared and Raman spectroscopy, differential scanning calorimetry. The comparison of the melting points and heats of fusions shows that the forms are monotropically related.


Asunto(s)
Antialérgicos/química , Modelos Químicos , Clorhidrato de Olopatadina/química , Absorción Fisicoquímica , Cristalización , Estructura Molecular , Solubilidad , Solventes/química , Agua/química
4.
Acta Biomater ; 41: 302-11, 2016 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-27221794

RESUMEN

UNLABELLED: Combination of the ability of contact lenses (CLs) to act as a physical barrier against airborne antigen and to serve as a sustained depot of antihistaminic drugs may improve the efficiency of treatments of some ocular allergic diseases. The aim of this work was to develop CLs that exhibit affinity to olopatadine by mimicking the composition of the natural H1-receptor for which olopatadine behaves as a selective antagonist. Functional monomers that match the chemical groups of the receptor and application of the molecular imprinting technology led to hydrogels able to load high amounts of olopatadine and to sustain the release once in contact with lachrymal fluid. Optimized hydrogels prepared with acrylic acid, 2-acrylamido-2-methyl-1-propanesulfonic acid and benzylmethacrylate as functional monomers provided in few hours olopatadine concentrations similar to those of commercially available eye drops but the levels could be sustained for a whole day, demonstrating their efficacy. Olopatadine-loaded CLs successfully passed the HET-CAM test of ocular irritancy and showed good compatibility with mast cells. They were able to inhibit the release of histamine and TNF-α from sensitized mast cells, proving their potential application in preventing and treating allergic conjunctivitis. STATEMENT OF SIGNIFICANCE: Contact lenses (CLs) with affinity for antiallergic drugs may constitute an advantageous alternative to eye drops in management of ocular allergies for both contact lens wearers and patients who eventually use neutral CLs as therapeutic platforms. The present work represents a step forward in the state of the art of drug-CL combo products by (i) mimicking the composition of the human receptor of the drug, (ii) exploring combinations of functional monomers that include a monomer (2-acrylamido-2-methyl-1-propanesulfonic acid; AMPSA) with a strong acid group (pKa<4) able to enhance the interaction of the network with olopatadine in the saline environment of the lachrymal fluid, and (iii) analysing in detail the antihistamic effects provided by olopatadine released from the CLs on sensitized mast cells.


Asunto(s)
Materiales Biomiméticos/uso terapéutico , Conjuntivitis Alérgica/tratamiento farmacológico , Lentes de Contacto , Clorhidrato de Olopatadina/uso terapéutico , Aminoácidos/química , Animales , Materiales Biomiméticos/farmacología , Línea Celular , Supervivencia Celular/efectos de los fármacos , Pollos , Conjuntivitis Alérgica/patología , Liberación de Fármacos , Histamina/metabolismo , Hidrogeles/síntesis química , Hidrogeles/química , Mastocitos/citología , Mastocitos/efectos de los fármacos , Ensayo de Materiales , Ratones , Impresión Molecular , Clorhidrato de Olopatadina/química , Clorhidrato de Olopatadina/farmacología , Factor de Necrosis Tumoral alfa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA